A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
TEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Not applicable.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 44M | 44M | 40M | 36M | 36M | 35M |
| Net Income | 7.7M | 7.7M | 8.0M | 6.6M | 3.9M | 3.2M |
| EPS | $0.01 | $0.01 | $0.05 | $0.04 | $0.02 | $0.02 |
| Free Cash Flow | 2.6M | 2.6M | 4.2M | 7.0M | 2.2M | 4.8M |
| ROIC | 15.3% | 17.0% | 19.8% | - | 12.4% | 10.0% |
| Gross Margin | 58.5% | 58.5% | 58.6% | 56.7% | 53.1% | 54.3% |
| Debt/Equity | 0.11 | 0.11 | 0.05 | - | 0.14 | 0.13 |
| Dividends/Share | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.01 |
| Operating Income | 584K | 584K | 597K | 873K | 457K | 176K |
| Operating Margin | 1.3% | 1.3% | 1.5% | 2.4% | 1.3% | 0.5% |
| ROE | 17.0% | 18.4% | 19.8% | - | 12.8% | 10.7% |
| Shares Outstanding | 833M | 833M | 163M | 163M | 163M | 152M |
DR REDDYS LABORATORIES LTD passes 3 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 41.7x vs a median of 3.8x. The company's 5-year average ROIC is 14.8% with a gross margin of 56.2%.
DR REDDYS LABORATORIES LTD (RDY) has a 5-year average return on invested capital (ROIC) of 14.8%. This indicates solid capital allocation.
DR REDDYS LABORATORIES LTD (RDY) has a market capitalization of $10.9B. It is classified as a large-cap stock.
Yes, DR REDDYS LABORATORIES LTD (RDY) pays a dividend with a trailing twelve-month yield of 0.01%.
DR REDDYS LABORATORIES LTD (RDY) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
DR REDDYS LABORATORIES LTD (RDY) reported annual revenue of $44 million in its most recent fiscal year, based on SEC EDGAR filings.
DR REDDYS LABORATORIES LTD (RDY) has a net profit margin of 17.6%. This is a healthy margin.
DR REDDYS LABORATORIES LTD (RDY) generated $3 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
DR REDDYS LABORATORIES LTD (RDY) has a debt-to-equity ratio of 0.11. This indicates a conservatively financed balance sheet.
DR REDDYS LABORATORIES LTD (RDY) reported earnings per share (EPS) of $0.01 in its most recent fiscal year.
DR REDDYS LABORATORIES LTD (RDY) has a return on equity (ROE) of 18.4%. This indicates the company generates strong returns for shareholders.
DR REDDYS LABORATORIES LTD (RDY) has a 5-year average gross margin of 56.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 10 years of financial data for DR REDDYS LABORATORIES LTD (RDY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
DR REDDYS LABORATORIES LTD (RDY) has a book value per share of $0.05, based on its most recent annual SEC filing.
No recent press releases.